EN 
ES 
Generic Myrbetriq Approved & Launched in US
The generic form of Myrbetriq has launched in the United States, following a lengthy and still ongoing legal battle from the manufacturer Astellas. A US district court in Delaware filed a report saying manufacturers should be allowed to launch the generic drug prior to the conclusion of the litigation.
Generic forms of the drug known as mirabegron are being manufactured by Zydus and Lupin and both have launched despite the possibility of a comeback from Astellas if they win their appeal.
The popular drug is an extended release selective beta3-adrenoceptor agonist therapy used to treat overactive bladders with symptoms of urge urinary incontinence, urgency and urinary frequency. The FDA approved the generic form of Myrbetriq in late 2022. The drug has a market value of $2.42 billion according to IQVIA data in February 2024.
Masters currently has limited stock of mirabegron with more supply expected soon as the generic manufacturers work to meet what is expected to be a large demand for the popular drug.